Nitric Oxide for Cardiac Surgery
(NORISC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to determine if inhaled nitric oxide can reduce complications after heart surgery involving a machine that maintains blood and oxygen flow. The focus is on minimizing serious issues such as heart failure, kidney problems, respiratory failure, and other major adverse events within 30 days post-surgery. Participants will receive either nitric oxide or standard care during and after surgery. Individuals undergoing planned heart or aortic surgery requiring a heart-lung machine, who have not had previous heart surgery, might be suitable candidates for this trial. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants the opportunity to contribute to a treatment nearing widespread availability.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are already on inhaled nitric oxide therapy or inhaled/aerosolized prostacyclin, you cannot participate in the trial.
Is there any evidence suggesting that inhaled nitric oxide is likely to be safe for humans?
Research has shown that inhaled nitric oxide (iNO) is generally safe for patients undergoing heart surgery. Earlier studies demonstrated that iNO improved blood flow and oxygen levels in patients with pulmonary hypertension during surgery. This treatment did not increase the need for blood or platelet transfusions, indicating good tolerance.
Early data also suggest that iNO can reduce signs of organ injury and complications in patients using a heart-lung machine during heart surgery. Other reports indicated that all patients who received iNO treatment were successfully discharged, and the treatment did not affect ventilator settings.
While these findings are encouraging, larger studies are still needed to confirm these benefits and ensure the treatment's safety for a broader patient population.12345Why do researchers think this study treatment might be promising?
Most treatments for heart conditions during surgery focus on maintaining blood flow and protecting the heart with medications like beta-blockers or calcium channel blockers. However, Nitric Oxide (NO) is unique because it targets the blood vessels directly, helping them widen and improve blood flow. Unlike standard treatments, NO is administered through inhalation during and after cardiopulmonary bypass, which could enhance oxygen delivery and reduce complications. Researchers are excited about this approach because it could lead to faster recovery times and better outcomes for patients undergoing heart surgery.
What evidence suggests that inhaled nitric oxide might be an effective treatment for cardiac surgery complications?
This trial will compare inhaled nitric oxide (iNO) with standard care in patients undergoing cardiac surgery. Research has shown that iNO can reduce the time patients spend on breathing machines after heart surgery and decrease certain indicators of organ damage and complications. This suggests it might improve heart and lung function post-surgery. However, previous studies did not find that iNO affected ICU or hospital stay durations, or survival rates. The main issue has been the small size of earlier studies, which makes it difficult to confirm its full benefits. Larger studies are needed to validate these findings.23678
Who Is on the Research Team?
Chong Lei, M.D., & phd
Principal Investigator
Xijing Hospital
Are You a Good Fit for This Trial?
This trial is for adults (18+) needing elective cardiac or aortic surgery with cardiopulmonary bypass. It's not open to those who've had previous open-heart surgeries.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive inhaled nitric oxide during cardiopulmonary bypass and postoperatively to reduce major adverse events
Follow-up
Participants are monitored for safety and effectiveness after treatment, including incidence of major adverse events and mortality
Extended Follow-up
Long-term monitoring of mortality and quality of life outcomes
What Are the Treatments Tested in This Trial?
Interventions
- Nitric Oxide
Trial Overview
The study tests if inhaling nitric oxide gas can reduce death and major complications like heart failure, kidney failure, respiratory issues, etc., within 30 days after surgery compared to standard care.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Patients will receive 80 parts per million (ppm) NO during CPB through the oxygenator. After weaning of CPB, test gases will be delivered via inspiration limb of ventilator at a dose range of 40-80 ppm until 6 hours after ICU admission or until extubation after surgery, whichever comes first.
Patients in this group will receive standard care and 80 ppm nitrogen (N2, control group) are added to the gas mixture as control. In the circumstances when the N2 is not applicable, such as when the plasma-chemical NO synthesis device is employed for NO generatiaon and delivery, the device will be connected to the CPB and ventilator circuits, but the synthesis will remain inactive in the control group. Consequently, the circuit will be supplied with air devoid of NO.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Xijing Hospital
Lead Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborator
Massachusetts General Hospital
Collaborator
Tianjin Chest Hospital, Tianjin, China
Collaborator
NORISC Trial Investigators
Collaborator
Nikolay O. Kamenshchikov., M.D., Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborator
Jiange Han, Tianjin Chest Hospital, Tianjin, China
Collaborator
Qingping Wu, Wuhan Union Hospital, Wuhan, China
Collaborator
Evgeniy Grigoriev, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation
Collaborator
Vladimir Boboshko, E. Meshalkin National Medical Research Center, Novosibirsk, Russian Federation
Collaborator
Published Research Related to This Trial
Citations
Inhaled nitric oxide and postoperative outcomes in cardiac ...
The results suggested that iNO could reduce the duration of mechanical ventilation, but had no significance in the ICU stay, hospital stay, and mortality.
Inhaled nitric oxide and postoperative outcomes in cardiac ...
The results suggested that iNO could reduce the duration of mechanical ventilation, but had no significance in the ICU stay, hospital stay, and mortality.
3.
clinicaltrials.gov
clinicaltrials.gov/study/NCT06702553?term=show%20wu%20pain&viewType=Table&checkSpell=&rank=9Nitric Oxide for Reduced Intensive Support in Cardiac ...
Preliminary data support the effect of inhaled NO on reducing biomarkers of organ injury and clinical signs of organ dysfunction in cardiac surgery under CPB.
Abstract 4142086: Efficacy And Safety Of Inhaled Nitric ...
Our analysis showed that iNO significantly reduced the duration of mechanical ventilation (MD = -5.733, 95% CI [-10.494; -0.972]). However, no ...
Beneficial effects of inhaled nitric oxide in adult cardiac ...
Inhaled nitric oxide effectively and selectively lowered right ventricular afterload and right ventricular work in critically ill adult cardiac patients.
Real-world safety and effectiveness of inhaled nitric oxide ...
INOflo treatment was a safe and effective strategy to improve hemodynamics and oxygenation in patients with pulmonary hypertension during cardiac surgery.
Real-world safety and effectiveness of inhaled nitric oxide ...
INOflo treatment was a safe and effective strategy to improve hemodynamics and oxygenation in patients with pulmonary hypertension during cardiac surgery.
8.
bmccardiovascdisord.biomedcentral.com
bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-025-04967-3Innovative nitric oxide delivery technology for postoperative ...
All patients received iNO treatment successfully and were discharged. The NO concentration remained stable, unaffected by ventilator settings, ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.